# A Phase II Multicenter, Randomized, Placebo Controlled, Double Blinded Clinical Study of KD018 as a Modulator of Irinotecan Chemotherapy in Patients With Metastatic Colorectal Cancer

> **NCT00730158** · PHASE2 · COMPLETED · sponsor: **Edward Chu, MD** · enrollment: 33 (actual)

## Conditions studied

- Colorectal Neoplasms

## Interventions

- **DRUG:** KD018
- **DRUG:** Irinotecan
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00730158
- **Lead sponsor:** Edward Chu, MD
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-12
- **Primary completion:** 2016-06
- **Final completion:** 2018-06
- **Target enrollment:** 33 (ACTUAL)
- **Last updated:** 2019-05-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00730158

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00730158, "A Phase II Multicenter, Randomized, Placebo Controlled, Double Blinded Clinical Study of KD018 as a Modulator of Irinotecan Chemotherapy in Patients With Metastatic Colorectal Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00730158. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*